Spots Global Cancer Trial Database for clinical response
Every month we try and update this database with for clinical response cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma | NCT00665470 | Skin Cancer Metastatic Mela... | Aldesleukin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Simvastatin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response and Tumor-Free Margin in Locally Advanced Breast Cancer | NCT04418089 | Breast Cancer Chemotherapy Ef... | Simvastatin 40m... Placebo oral ca... | - | Indonesia University | |
| CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | NCT01218867 | Metastatic Canc... Metastatic Mela... Renal Cancer | Anti-VEGFR2 CAR... Cyclophosphamid... Aldesleukin Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma | NCT00314106 | Metastatic Mela... | Melanoma Reacti... Cyclophosphamid... IL-2 Fludarabine 1200 total body... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Infliximab Efficacy, TDM and Serum TNFα Levels in Pediatric HSCT Recipients With aGVHD: Prospective Observational Study | NCT05362630 | Graft Versus Ho... Hematopoietic S... | - 18 Years | University of Pisa | ||
| Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma | NCT00924001 | Melanoma Malignant Melan... Melanoma, Exper... | DMF5 Melanoma R... Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Effect of Talactoferrin in Adults With Non-Small Cell Lung Cancer | NCT00923741 | Non-Small Cell ... | Talactoferrin Apheresis | 18 Years - 90 Years | National Institutes of Health Clinical Center (CC) | |
| Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer | NCT00091611 | Kidney Neoplasm... | IL-2 (interleuk... OKT3 Cyclophosphamid... Fludarabine Mesna | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| RFT-5-dgA in Patients With Metastatic Melanoma | NCT00314093 | Metastatic Mela... | RFT5pdgA | 18 Years - | University of Texas Southwestern Medical Center | |
| Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer | NCT00328861 | Metastatic Mela... Metastatic Kidn... | Natural Killer ... IL-2 Cyclophosphamid... Fludarabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Infliximab Efficacy, TDM and Serum TNFα Levels in Pediatric HSCT Recipients With aGVHD: Prospective Observational Study | NCT05362630 | Graft Versus Ho... Hematopoietic S... | - 18 Years | University of Pisa | ||
| Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma | NCT00924001 | Melanoma Malignant Melan... Melanoma, Exper... | DMF5 Melanoma R... Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | NCT01218867 | Metastatic Canc... Metastatic Mela... Renal Cancer | Anti-VEGFR2 CAR... Cyclophosphamid... Aldesleukin Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Metronomic Capecitabine and Oxaliplatin Versus XELOX in Egyptian Metastatic Colorectal Cancer Patients | NCT04425564 | Clinical Respon... Toxicity Survival | metronomic XELO... Classic XELOX Blood samples f... | 19 Years - 70 Years | National Cancer Institute, Egypt | |
| Clinical Evaluation of Neoadjuvant Chemotherapy for Primary Malignant Sarcomas That Originate in Bone | NCT03742063 | Clinical Respon... Histopathologic... Prognosis | first-line chem... | - | Peking University People's Hospital | |
| CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | NCT01218867 | Metastatic Canc... Metastatic Mela... Renal Cancer | Anti-VEGFR2 CAR... Cyclophosphamid... Aldesleukin Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma | NCT00513604 | Melanoma Malignant Melan... Melanoma, Exper... Experimental Me... | aldesleukin therapeutic aut... Cyclophosphamid... Fludarabine pho... Total body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease | NCT02768532 | Crohn Disease | Vedolizumab | 18 Years - | Centre Hospitalier Universitaire de Saint Etienne | |
| Simvastatin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response and Tumor-Free Margin in Locally Advanced Breast Cancer | NCT04418089 | Breast Cancer Chemotherapy Ef... | Simvastatin 40m... Placebo oral ca... | - | Indonesia University | |
| The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer | NCT05550415 | Triple Negative... Chemotherapy Ef... Simvastatin Adv... | Simvastatin 40m... Placebo | 18 Years - | Indonesia University | |
| A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma | NCT00062933 | Melanoma | Laparotomy | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Cancer Vaccine Targeting Brachyury Protein in Tumors | NCT01519817 | Neoplasms Malignant Solid... Colon Neoplasms Adenocarcinoma | GI-6301 (Yeast ... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease | NCT00552058 | Crohn Disease | certolizumab pe... Placebo | 18 Years - 75 Years | UCB Pharma | |
| 90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma | NCT01157988 | Lymphoma, Large... | ibritumomab tiu... | 18 Years - | Chonnam National University Hospital | |
| Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma | NCT00314106 | Metastatic Mela... | Melanoma Reacti... Cyclophosphamid... IL-2 Fludarabine 1200 total body... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma | NCT00924001 | Melanoma Malignant Melan... Melanoma, Exper... | DMF5 Melanoma R... Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease | NCT00552058 | Crohn Disease | certolizumab pe... Placebo | 18 Years - 75 Years | UCB Pharma | |
| A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma | NCT00062933 | Melanoma | Laparotomy | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Sleep and Immune Checkpoint Inhibitors | NCT04070651 | Lung Cancer | 18 Years - | Aarhus University Hospital | ||
| Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma | NCT00001832 | Melanoma Neoplasm Metast... | gp100:209-217 (... Montanide ISA-5... IL-2 MART-1:26-35(27... Abl cells Fludarabine Cyclophosphamid... GCSF (Growth co... Apheresis | 7 Years - | National Institutes of Health Clinical Center (CC) | |
| Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma | NCT00924001 | Melanoma Malignant Melan... Melanoma, Exper... | DMF5 Melanoma R... Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer | NCT00328861 | Metastatic Mela... Metastatic Kidn... | Natural Killer ... IL-2 Cyclophosphamid... Fludarabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma | NCT00513604 | Melanoma Malignant Melan... Melanoma, Exper... Experimental Me... | aldesleukin therapeutic aut... Cyclophosphamid... Fludarabine pho... Total body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
